Exodus Technology

Company Overview

Snapshot

Founded in January 2023 by Michael Zilbershlag, Exodus Technology operates with 1–10 employees. The company has raised $150,000 across one funding round from one investor. Exodus Technology is developing a groundbreaking nanoparticle-based solution for chronic pain relief, addressing a significant global health challenge.

Business overview

Exodus Technology offers Focus Pain Ablation (FPA) technology, a non-drug solution for targeted, permanent chronic pain relief. The core technology utilizes gold nanoparticles conjugated with a neuronal tracer, injected into the painful area and activated by external ultrasound energy to selectively destroy sensory nerve cell bodies in the Dorsal Root Ganglion (DRG), thereby silencing pain signals. This innovation targets the massive global burden of chronic pain, particularly aiming to replace repeat-intensive procedures and long-term drug dependence. The initial application focuses on Knee Osteoarthritis Pain, serving the Health Tech & Life Sciences sector with a B2B2C and B2B business model.

Strategic signal

In October 2025, Exodus Technology's nanoparticle-based solution for chronic pain was highlighted in news reports for its potential to save billions in traditional painkiller costs and target a $78 billion market opportunity. This signals strong market validation and investor interest in innovative, non-opioid alternatives for chronic pain management, positioning the company as a key player in addressing the opioid crisis and improving patient outcomes.

Company Intelligence Q&A

What is Exodus Technology's primary solution for chronic pain?

Exodus Technology offers Focus Pain Ablation (FPA) technology, a nanoparticle-based, non-drug solution designed for targeted and permanent chronic pain relief. This method aims to provide a lasting alternative to traditional pain management approaches.

When was Exodus Technology founded and by whom?

Exodus Technology was founded in January 2023 by Michael Zilbershlag.

What is the core mechanism of Exodus Technology's FPA technology?

The FPA technology uses gold nanoparticles conjugated with a neuronal tracer. These are injected into the painful area, transported to the Dorsal Root Ganglion (DRG), and then activated by external ultrasound energy to destroy specific sensory nerve cell bodies, silencing the pain signal.

What market opportunity is Exodus Technology addressing?

Exodus Technology is addressing the global health and economic burden of chronic pain, which affects approximately 20% of the adult Western population. The company aims to provide alternatives to the $78.41 billion global drug market for pain relief, particularly in light of the opioid crisis.

What is the initial application target for Exodus Technology's FPA technology?

The initial application for Exodus Technology's FPA technology targets Knee Osteoarthritis Pain, a condition affecting 300 million people worldwide.